Alx Oncology Holdings Inc. · NASDAQ:ALXO
Alx Oncology — SITC 2018
7 slides from Alx Oncology's conference presentation, November 2018
Slide 1: A Phase 1 Study of ALX148: CD47 Blockade in Combination with Anti-Cancer Antibodies
A Phase 1 Study of ALX148: CD47 Blockade in Combination with Anti- Cancer Antibodies to Bridge Innate and Adaptive Immune Responses for Advanced Malignancy (#P335) Nehal Lakhani,1 Patricia LoRusso,2 Laura Q Chow,3 Yung-Jue Bang,4 Justin Gainor,5 Jeeyun Lee,6 Hyun Chung,7 Keun-Wook Lee,8 Stephen Hodi
Slide 2: Disclosures
Disclosures • ALX Oncology • InhibRx • Amgen • Incyte • Arqule • Macrogenics • Ascentage • Loxo • Apexian • Livzon Mabpharm • Asana Biosciences • Merck • Formation Biologics • Northern Biologics • Beigene • Pfizer • Constellation Pharma • Regeneron • CytomX • Symphogen • Daiichi Sankyo • TaiRx • For
Slide 3: ALX148: A Unique High Affinity SIRPα Fusion Protein
ALX148: A Unique High Affinity SIRPα Fusion Protein • CD47, a marker of self, is upregulated by tumors to evade the immune system • CD47-SIRPα signaling represents a myeloid checkpoint mechanism in cancer • CD47 engages SIRPα and signals the macrophage to ignore the cell on which it is expressed ALX
Slide 4: AT148001 Phase 1 Study Design and Combination Demography
AT148001 Phase 1 Study Design and Combination Demography Data Cutoff 12Oct2018 Part 1 ALX148 Single Agent – enrollment complete +Pembrolizumab* +Trastuzumab • Primary: Safety DLT; Secondary: Response, PK/PD n=39 n=18 Dose Median Age, yr (range) 59 (32-79) 57 (45-71) Cohort Schedule mg/kg F 20 7 1 0.
Slide 5: ALX148 Generally Well Tolerated in Combination with Standard Regimens of Pembrolizumab and Trastuzumab
ALX148 Generally Well Tolerated in Combination with Standard Regimens of Pembrolizumab and Trastuzumab Data Cutoff 12Oct2018 Treatment Related Adverse Events ≥ Treatment Related Adverse Grade 3 in any Patient Events in ≥ 2 Patients ALX148+Pembrolizumab (N=39) ALX148 Exposure/Patient Disposition ALX1
Slide 6: Preliminary Anti-Cancer Activity Seen Across all ALX148 Combinations and Tumor Histologies in Expansion Cohorts
Preliminary Anti-Cancer Activity Seen Across all ALX148 Combinations and Tumor Histologies in Expansion Cohorts Data Cutoff 25Oct2018 64 yo pt with NSCLC-adenocarcinoma Response Summary (TPS 10%,CMET/TP53) • NSCLC ALX148 + pembrolizumab: 16 evaluable patients (progressed on prior CPI and/or TPS<50%)
Slide 7: AT148001: Conclusions
AT148001: Conclusions Intended for combination, ALX148 is designed to avoid the dose-limiting toxicities associated with other CD47-targeted approaches in the clinic, while maximizing the efficacy of antibody-based therapies • No MTD was reached with ALX148 in combination. The maximum administered d